Barclays’s bioAffinity Technologies BIAF Stock Holding History

Barclays’s Portfolio BIAF Stock Details BIAF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-106	Closed	-$827	–	5267
2025 Q1	$827	Buy	+106	New	+$1.94K	﹤0.01%	5061

Other funds holding BIAF

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Barclays's BIAF Position: Q2 2025 in Review

Barclays sold out of bioAffinity Technologies (BIAF) in Q2 2025, closing a stake of 106 shares — an estimated $827 sold.

Barclays first reported a position in BIAF in Q1 2025 and held it in 1 quarter. The position peaked at $827 in Q1 2025. 17 funds tracked by Wall St. Rank hold BIAF as of Q2 2025.

Barclays reported no remaining bioAffinity Technologies position as of Q2 2025 after selling out during the quarter.
Barclays sold 106 bioAffinity Technologies shares in Q2 2025, an estimated $827.
Barclays first reported a position in bioAffinity Technologies in Q1 2025 and held it in 1 quarter.
Barclays's bioAffinity Technologies position peaked at $827 in Q1 2025.
17 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.